Company intelligence / Profile preview

SmartCardia

Lausanne, Switzerland

Ownership: Private
Development stage: Other

Overview

SmartCardia has received FDA clearance for multiple cardiac monitoring modalities including Extended Holter (September 2023), Event and Holter monitoring, and Mobile Outpatient Cardiac Telemetry (November 2024). The company has CE Class IIa approval in Europe and is commercially active in Europe and India with expansion to other regions.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on SmartCardia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SmartCardia.

Explore the full profile